

26<sup>th</sup> September, 2024

The Dy. General Manager (Listing Dept.)  
BSE Limited.,  
Corporate Relationship Dept.,  
1st Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
**(BSE Scrip Code: 500420)**

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
**(NSE Scrip Code: TORNTPHARM)**

Dear Sir,

**Sub.: Torrent Pharmaceuticals Limited (Torrent) refutes claims of Shelcal 500 allegedly failing CDSCO quality test**

---

A press release issued by the Company with respect to captioned subject is attached for your information and record.

Kindly take note of the above.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI  
COMPANY SECRETARY

---

**TORRENT PHARMACEUTICALS LIMITED**

CIN: L24230GJ1972PLC002126

Reg.Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100,  
www.torrentpharma.com, Email : InvestorServices@TorrentPharma.com

## **Torrent Pharmaceuticals Limited (Torrent) refutes claims of Shelcal 500 allegedly failing CDSCO quality test**

- *The sample seized by CDSCO is not manufactured by Torrent and is in fact non-genuine and spurious.*
- *All products manufactured and marketed by Torrent follow Good Manufacturing Practices (GMP) and are controlled through pre-established specifications and/or regulatory norms*

**Ahmedabad, India September 26<sup>th</sup> 2024:** Recent articles have been issued in media with reference to the Central Drugs Standard Control Organization (CDSCO) East Zone, Kolkata report referring to one batch (GDXD0581) sample of Product Shelcal 500, amongst other drugs marketed by various pharmaceutical companies, allegedly being non-standard quality (NSQ).

To verify the genuineness of the sample collected by CDSCO, a comparative evaluation was carried out with our controlled sample of the same batch. The outcome of the analysis concluded that the sample seized by CDSCO is not manufactured by Torrent and is in fact non-genuine and spurious.

As anti-counterfeit measures, Torrent has implemented QR codes on Shelcal, displaying batch manufacturing details to verify its authenticity, which was found to be lacking in the sample seized by CDSCO.

Our assessment of establishing authenticity of samples including physical appearance, QR code and labelling text comparison establishes that the NSQ sample is non-genuine and counterfeit, whereas our controlled sample matches with pre-defined specifications.

Torrent has already submitted a formal response along with assessment report, concluding the seized sample as spurious to CDSCO.

Each and every batch manufactured is also subjected to strict quality testing. We assure that all products manufactured and marketed by Torrent follow Good Manufacturing Practices (GMP) and are controlled through pre-established specifications and/or regulatory norms.

In case of any enquiry / clarification, please contact Mr. Jayesh Desai on +91 9824501396

**TORRENT PHARMACEUTICALS LIMITED**

CIN : L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad - 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100, [www.torrentpharma.com](http://www.torrentpharma.com)

## MEDIA RELEASE



### **About Torrent Pharmaceuticals Ltd:**

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of more than ~Rs 41,000 crores. It is ranked 5th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS), and Vitamins Minerals Nutritional (VMN) and Cosmo-Dermatology.

It is a specialty-focused company with ~75% of its revenues in India from chronic & sub-chronic therapies. It has presence in 50+ countries and is ranked No. 1 amongst the Indian pharma Companies in Brazil and Germany. Torrent has 8 manufacturing facilities, of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing approximately 750+ scientists.

In case of any enquiry / clarification, please contact Mr. Jayesh Desai on +91 9824501396

### **TORRENT PHARMACEUTICALS LIMITED**

CIN : L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad - 380 009, India. Phone: +91 79 26599000, Fax : +91 79 26582100, [www.torrentpharma.com](http://www.torrentpharma.com)